Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
AJR. American Journal of Roentgenology|February 21, 2004
High-resolution CT using MDCT: comparison of degree of motion artifact between volumetric and axial methodsD M Kelly, I Hasegawa, R Borders, et al.International Journal of Palliative Nursing|July 22, 2021
Opioid epidemic and prescribing in hospice and palliative care: a review of the literatureJoshua R Borders, Susan Letvak, Karen A Amirehsani, et al.Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|April 29, 2026
Reusing the workhorse: Outcomes after secondary inset of paraspinous muscle flapsParhom Towfighi, Kathryn R Borders, Ryan Harmelink, et al.Journal of Cognitive Engineering and Decision Making|March 15, 2016
Designing Colorectal Cancer Screening Decision Support: A Cognitive Engineering EnterpriseLaura G Militello, Jason J Saleem, Morgan R Borders, et al.Applied Clinical Informatics|February 16, 2017
Evaluating a Modular Decision Support Application For Colorectal Cancer ScreeningLaura G Militello, Julie B Diiulio, Morgan R Borders, et al.Bioorganic & Medicinal Chemistry|May 24, 2015
Preparation and biological evaluation of conformationally constrained BACE1 inhibitorsLeonard L Winneroski, Matthew A Schiffler, Jon A Erickson, et al.Journal of Alzheimer'S Disease Reports|March 4, 2022
Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical SpeciesBrian A Willis, Stephen L Lowe, Scott A Monk, et al.Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.Pageof 1